Levetiracetam (LEV), for example, showed a positive trend in a clinical trial, 44 supported by preclinical data, 45 and is currently under reevaluation in the fluid percussion injury (FPI) model in rats by the EpiBioS4Rx consortium. 46 Other repurposed drugs with differing mechanisms of action have also shown disease‐modification effects in rodent models of PTE.
← all excerpts
A consensus roadmap for post-traumatic epilepsy: Clinical biomarkers, research priorities, policy barriers, and pathways to interventional trials.
1
—
—